Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Lung Neoplasms 2Stomach Neoplasms 1Sarcoma, Synovial 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma 1Leukemia, Myeloid 1Glioma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1

Interventions

pembrolizumab 92Nivolumab 57Cyclophosphamide 22Ipilimumab 17atezolizumab 15Magnetic Resonance Spectroscopy 14Specimen Handling 13Radiosurgery 13Paclitaxel 13Interleukin-2 12Docetaxel 12fludarabine 11Carboplatin 11Pemetrexed 10spartalizumab 9Biopsy 9durvalumab 8Cisplatin 8Radiotherapy 7Immune Checkpoint Inhibitors 7Blood Specimen Collection 7cemiplimab 6avelumab 6aldesleukin 6Taxes 6Gemcitabine 6Drug Therapy 6Bevacizumab 6trametinib 5tislelizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Immunotherapy, Adoptive × Thoracic × Clear all
NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡